WALTHAM, Mass., June 22 /PRNewswire/ --
AltaRex Corp. (OTC: ALXFF; Toronto: AXO) will present an update of the
Company's clinical and partnering progress in a live audiocast being held at
4:45 p.m. (PST) on Tuesday, June 26 at the BIO 2001 International Convention
in San Diego, California. Vice President of Business Development Robert
Newman will update the audience on the Company's clinical development program
for its lead product OvaRex(R) MAb, and will address established corporate
collaborations and plans for additional collaborations.
(Photo: http://www.newscom.com/cgi-bin/prnh/20000831/ALTREXLOGO )
Individuals can access the audiocast of this presentation by linking to:
http://www.informedinvestors.com/iif_forums/client_capsule.cfm?CompanyID=695
The link to the audiocast is located below the AltaRex profile, and will
also be available on Company website at http://www.altarex.com .
Additionally, a recent In Profile interview of AltaRex President and CEO
Richard Bagley will be available by June 26 at http://www.virtuecast.com . A direct
link to the interview will then be posted on the AltaRex website. The
interview will be featured on the Virtuecast site for one week.
About AltaRex
AltaRex Corp. is focused on the research, development and
commercialization of antigen-targeted antibody-based cancer therapies,
utilizing monoclonal antibodies as immunotherapeutic agents for the treatment
of certain late-stage cancers. The Company's lead product OvaRex(R) MAb
targets the tumor associated antigen CA 125 and is in final stages of clinical
evaluation for the treatment of advanced ovarian cancer. Clinical data
reported from completed and ongoing OvaRex(R) trials demonstrate patient
benefit as measured by prolongation in time to relapse and/or survival,
without the toxicities seen with standard chemotherapies. The compilation of
OvaRex(R) data from six clinical studies in over 500 ovarian cancer patients
will form the basis for a simultaneous filing for approval of OvaRex(R) MAb
with both the U.S. and Canadian regulatory authorities, a process anticipated
to begin in late 2001 or early 2002, assuming timely scale-up of cell culture
manufacturing. The Company believes that the BrevaRex(R) MAb targets the
tumor associated antigen MUC1 and has completed a phase I safety and
immunology study, with a phase I/II study in multiple myeloma patients
scheduled to open during the third quarter of this year.
More about AltaRex research and development, clinical trials, news and
events can be found on its web site at http://www.altarex.com. AltaRex Corp. is
traded on the Toronto Stock Exchange under the symbol AXO, and
over-the-counter in the United States under the symbol ALXFF. Clinical trial
information can be found at http://www.centerwatch.com . Additional information
about ovarian cancer can be found at http://www.nci.nih.gov , http://www.ovarian.org ,
http://www.ovariancancer.org and at http://www.ovariancanada.org . Additional information
about multiple myeloma can be found at http://www.multiplemyeloma.org .
This news release contains forward-looking statements that involve risks
and uncertainties, which may cause actual results to differ materially from
the statements made. For this purpose, any statements that are contained
herein that are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the foregoing, the words
"believes," "anticipates," "plans," "intends," "expects" and similar
expressions are intended to identify forward-looking statements. Such risks
and uncertainties include, but are not limited to our need for capital and the
risk that the Company can not raise funds on a timely basis on satisfactory
terms or at all, changing market conditions, completion of clinical trials,
patient enrollment rates, uncertainty of pre-clinical, retrospective and early
clinical trial results, which may not be indicative of results that will be
obtained in ongoing or future clinical trials, the establishment of
manufacturing processes and new corporate alliances, the timely development,
regulatory approval and market acceptance of the Company's products,
uncertainty as to whether patents will issue from pending patent applications
and, if issued, as to whether such patents will be sufficiently broad to
protect the Company's technology, and other risks detailed from time-to-time
in the Company's filings with the United States Securities and Exchange
Commission and Canadian securities authorities.
THE TORONTO STOCK EXCHANGE HAS NOT APPROVED OR DISAPPROVED OF THE
INFORMATION CONTAINED HEREIN.
SOURCE AltaRex Corp.
 back to top
Related links:
http://www.altarex.com
http://www.informedinvestors.com/iif_forums/client_capsule.cfm?CompanyID=695
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/20000831/ALTREXLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/comp/128163.html or fax,
800-758-5804, ext. 128163
CONTACT:
Sondra Henrichon, Director, Investor
Relations and Corporate Communications of AltaRex Corp.,
781-672-0138, ext. 1510, or shenrichon@altarex.com; or Wayne
Hendry, Investor Relations of The Equicom Group, Inc.,
416-815-0700, ext. 238, or whendry@equicomgroup.com, for AltaRex
Corp.
|
